Search hospitals > Connecticut > Orange
Smilow Cancer Hospital-Orange Care Center
Claim this profileOrange, Connecticut 06477
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Breast cancer
Conducts research for Pancreatic Cancer
Conducts research for Non-Small Cell Lung Cancer
100 reported clinical trials
28 medical researchers
Summary
Smilow Cancer Hospital-Orange Care Center is a medical facility located in Orange, Connecticut. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer and other specialties. Smilow Cancer Hospital-Orange Care Center is involved with conducting 100 clinical trials across 160 conditions. There are 28 research doctors associated with this hospital, such as Joseph W. Kim, MD, Debra S. Brandt, Hari A. Deshpande, and Michael Cecchini.Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
Joseph W. Kim, MDYale University9 years of reported clinical research
Studies Prostate Cancer
Studies Bladder Cancer
14 reported clinical trials
27 drugs studied
Debra S. BrandtJupiter Medical Center2 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
9 reported clinical trials
21 drugs studied
Hari A. DeshpandeYale University8 years of reported clinical research
Studies Cancer
Studies Thyroid Cancer
7 reported clinical trials
15 drugs studied
Michael CecchiniYale University4 years of reported clinical research
Studies Pancreatic Cancer
Studies Colorectal Cancer
8 reported clinical trials
15 drugs studied
Clinical Trials running at Smilow Cancer Hospital-Orange Care Center
Lung Cancer
Multiple Myeloma
Pancreatic Cancer
Non-Small Cell Lung Cancer
Pancreatic Neuroendocrine Tumors
Breast Cancer
ALK Gene Rearrangement
Colon Cancer
Small intestine cancer
Small Intestinal Adenocarcinoma
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Smilow Cancer Hospital-Orange Care Center?
Smilow Cancer Hospital-Orange Care Center is a medical facility located in Orange, Connecticut. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer and other specialties. Smilow Cancer Hospital-Orange Care Center is involved with conducting 100 clinical trials across 160 conditions. There are 28 research doctors associated with this hospital, such as Joseph W. Kim, MD, Debra S. Brandt, Hari A. Deshpande, and Michael Cecchini.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.